期刊
MEDICAL CLINICS OF NORTH AMERICA
卷 100, 期 4, 页码 911-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mcna.2016.03.012
关键词
Antimicrobial resistance; Soft tissue abscess; Intraabdominal abscess; Dalbavancin; Oritavancin; Ceftaroline fosamil; Ceftolozane-tazobactam; Ceftazidime-avibactam
Antimicrobial drug-resistance continues to force adaptation in our clinical practice. We explore new evidence regarding adjunctive antibiotic therapy for skin and soft tissue abscesses as well as duration of therapy for intra-abdominal abscesses. As new evidence refines optimal practice, it is essential to support clinicians in adopting practice patterns concordant with evidence-based guidelines. We review a simple approach that can 'nudge' clinicians towards concordant practices. Finally, the use of novel antimicrobials will play an increasingly important role in contemporary therapy. We review five new antimicrobials recently FDA-approved for use in drug-resistant infections: dalbavancin, oritavancin, ceftaroline, ceftolozane-tazobactam, and ceftazidime-avibactam.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据